Consistent with prior studies of ovarian cancers, our results suggest that BRCA1/2 mutation-associated malignancies accrue most of their genomic scarring and mutations early in tumorigenesis, and increasing genomic instability is not a major factor driving recurrence. This evidence concerns the gene BRCA1 and ovarian carcinoma.